Updates
** Shares of generic drugmaker Viatris VTRS.O fall as much as 22% to over a year low of $8.77
** Stock last down 14% at $9.67 in afternoon trade
** Company forecast 2025 revenue to be between $13.5 billion and $14 billion, below analysts' estimate of $14.27 billion — LSEG
** Expects 2025 adj profit between $2.12/share and $2.26/share, compared with estimates of $2.59/share
** VTRS says it estimates FDA action will negatively impact its 2025 total revenues by about $500 million and adjusted core earnings by roughly $385 million
** Last year, FDA has restricted imports from Viatris' Indore facility in India due to regulatory violations
** VTRS also reports fouth-quarter adj profit of 54 cents/share, below analysts' estimate of 57 cents/share
** Posts quarterly sales of $3.52 billion, below analysts' est of $3.61 billion
** VTRS gained 8.6% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.